Lexicon Pharmaceuticals, Inc. is a US-based pharmaceutical company with a medium risk assessment, as per its ESG score of 25.0. Specializing in the discovery, development, and commercialization of pharmaceutical products, the company offers drug candidates like LX9211 for neuropathic pain and sotagliflozin for heart failure and type 1 diabetes treatment.